Form 4: IO Biotech Director Peter Hirth Granted 35,144 Stock Options

IO Biotech, Inc. Director Peter Hirth was granted 35,144 stock options with an exercise price of $1.50, vesting in June 2026.

Summary

• Peter Hirth, a Director of IO Biotech, Inc. (IOBT), was granted 35,144 stock options.
• The options have an exercise price of $1.50 per share.
• The transaction date for the option grant was June 5, 2025.
• These options are scheduled to vest on June 5, 2026, contingent upon Mr. Hirth's continued service.
• The options have an expiration date of June 5, 2035.
• A clause for 100% acceleration of vesting upon a change of control is included.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents standard director compensation and aligns interests, but not a significant market-moving event.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The stock options granted to Director Peter Hirth are set to vest on June 5, 2026, provided he continues his service. Additionally, the options include a provision for 100% accelerated vesting in the event of a change of control, indicating potential future scenarios for the company.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align their interests with long-term company performance and shareholder value creation.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value if the stock price increases above the exercise price.

Next Steps

• The options will vest on June 5, 2026, subject to Peter Hirth's continued service.

Key Dates

Keywords

IO Biotech, IOBT, Peter Hirth, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant